Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
← catalyst calendarNCT07684144 · readout in 494 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
950estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-29 | estimated | When the study began enrolling |
| Primary completion | 2027-12-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-19 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
- Diabetes Mellitus, Type 2
Interventions
- Drug: Maridebart Cafraglutide — also filed as AMG 133, MariTide
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercent Change in Body Weight from Baseline of the Parent Trial (20210184)
measured Baseline of parent trial (20210184) to Week 48 of current trial
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
measured Baseline of current trial up to 60 weeks
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed